Sam Fazeli, Director of Research for Global Industries and Senior Pharmaceuticals Analyst for Bloomberg Intelligence, joined Bloomberg's Scarlett Fu and Paul Sweeney to discuss the gains and losses in the GLP1 market. (Source: Bloomberg)
Sam Fazeli, Director of Research for Global Industries and Senior Pharmaceuticals Analyst for Bloomberg Intelligence, joined Bloomberg's Scarlett Fu and Paul Sweeney to discuss the gains and losses in the GLP1 market. (Source: Bloomberg)
<iframe src="https://statesidedaily.com/embed/cluster/2678738000d62e1e24da7efef757a45a0d9addfc" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Lilly's Weight Loss Sets High Bar for Obesity Drug Race"></iframe>
